Lyell Immunopharma, Inc. Payments of Stock Issuance Costs
Lyell Immunopharma, Inc. (LYEL) reported Payments of Stock Issuance Costs of $33.20 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2024-02-28
- Lyell Immunopharma, Inc. payments of stock issuance costs for the quarter ending 2021-12-31 was $0.00.
- Lyell Immunopharma, Inc. payments of stock issuance costs for the quarter ending 2021-09-30 was $39.00K.
- Lyell Immunopharma, Inc. payments of stock issuance costs for the quarter ending 2021-06-30 was $33.16M.
- Lyell Immunopharma, Inc. payments of stock issuance costs for fiscal 2021 was $33.20M.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $39.00K derived: sum of 2 quarters · filed 2024-02-28 | $33.20M derived: sum of 3 quarters · filed 2024-02-28 | $33.20M 10-K · filed 2024-02-28 |
| 2021-09-30 | $39.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $33.20M derived: sum of 2 quarters · filed 2022-11-08 | $33.20M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $33.16M 10-Q · filed 2022-08-04 | $33.16M 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |